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Repeatedly heated mix vegetable oils-
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Murraya koenigii
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Abstract
Background: Statins are considered as standard drugs to control cholesterol levels, but their use is also associated
with renal hypertrophy, hemorrhagic stroke, hepatomegaly, and myopathy. Murraya koenigii is an herb that is used
in traditional cuisine and as a medicine in South Asia. Here we assessed the antidyslipidemic and antiatherosclerotic
effects of this spice in repeated heated mix vegetable oils (RHMVO)-induced atherosclerotic models.
Methods: Aqueous extract of M. koenigii leaves (Mk LE) was prepared and its phytoconstituents were determined.
Rabbits were divided into 5 groups (n = 10). Except for the control group, all the other four groups were treated
with RHMVO for 16 weeks (dose = 2 ml/kg/day) to induce dyslipidemia and atherosclerosis. These groups were
further treated for 10 weeks either with 300 and 500 mg/kg/day Mk LE, lovastatin, RHMVO, or left untreated. Body
and organ weights were measured along with oxidative stress and tissue damage parameters. Lipid profile and
hepatic function markers were studied. Atheroma measurement and histopathological examination were also
performed in control and treated groups.
Results: Mk LE significantly (p < 0.05) attenuated RHMVO-induced dyslipidemia and atheroma formation.
Furthermore, fat accumulation and lipid peroxidation in hepatic tissues were reduced by Mk LE in a dose-
dependent manner. Our results indicated that the antidyslipidemic effects of Mk LE in 500 mg/kg/day dose were
comparable to lovastatin. Additionally, oxidative stress markers were reduced much more significantly in Mk LE-500
than in the statin group (p < 0.05).
Conclusions: This study recommends Mk LE as a potent antioxidant and lipid-lowering natural medicine that can
attenuate the RHMVO-induced atherosclerotic in optimal doses and duration. Therefore, Mk LE can be accessible,
cheap, and free of adverse effects alternate to statins.
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Background
In modern society, altered food consumption pattern
increases incidences of metabolic syndrome, including
obesity, hypertension, diabetes, atherosclerosis, stroke,
and cancer [1–4]. Particularly dyslipidemia is consid-
ered as the basic cause of health concerns, related to
metabolic syndrome [2]. As per National Cholesterol
Education Program Adult Treatment Panel III
(NCEP-ATP) guidelines, dyslipidemia is characterized
as triglycerides (TG) > 150 mg/dl, total serum choles-
terol (TC) > 200 mg/dl, low-density lipoproteins (LDL)
> 100 mg/dl and high-density lipoproteins (HDL) less
than 40 mg/dl. Dyslipidemia is the most important
risk factors of cardiovascular diseases (CVDs) and
atherosclerosis [5, 6].
Cholesterol is transported to the liver for metabolism,
by HDL, whereas endothelial injuries and formation of
atheroma are triggered by oxidized LDL molecule.
Therefore, reduction of LDL and TC, along with HDL
level enhancement is targeted to prevent atherosclerosis
[7]. So far, statins have been utilized for inhibiting chol-
esterol biosynthesis, by restraining 3-hydroxy-3-
methylglutary-coenzyme A (HMG-CoA). In addition,
statins induce the cellular level of LDL receptors activity
that in turn facilitates the metabolism of LDL and very-
low-density lipoproteins (VLDL) [8, 9]. However, despite
this benefit, long-term use, and/or over-dosage of statins
results in serious adverse effects, such as renal hyper-
trophy, hemorrhagic stroke, hepatomegaly, and myop-
athy [10–12]. These facts are driving the researchers to
explore the solution from nature to regulate blood flow
and control the blood cholesterol levels, with the least
adverse effects.
Physico-chemical characteristics of the cooking oils
change when they are heated beyond a certain limit as
several chemical reactions take place in the presence of
moisture and air. Oils degenerate and produce volatile
substances, unwanted monomers, polymers, isomers,
and free radicals [13]. In cooking oil fatty acids (FAs)
naturally exist in the cis-isomer form, but during ther-
mal oxidation they convert into trans-isomers, posses-
sing physical properties similar to saturated FAs [14].
Several animal studies demonstrate that consumption of
thermally oxidized vegetable oils increased the risk of
CVDs, like hypertension with reduced vasorelaxation re-
sponses [15], endothelial malfunction [16], lipid peroxi-
dation [17], atherosclerosis [18], and oxidative stress
[19]. However, regardless of all these studies, the prac-
tice of reusing and overheating the cooking oils while
processing the food seems to continue.
M. koenigii (curry leaves) are commonly used spices in
Pakistani cuisine. With the vast range of biological activ-
ities such as antidyslipidemic [20–22], platelet aggrega-
tion inhibiting [23], antioxidant [24], and hypoglycemic
activities [25], it gained the attention of researchers
worldwide. Several animal studies have reported this
spice as a potent antidyslipidemic agent and the re-
sponse was achieved in 4–8 weeks, in a dose-dependent
manner [20, 21]. A recent human study, conducted on
45–65 years women of postmenopausal phase with
hyperlipidemia, also reported that M. koenigii leaves in-
take for 45 consecutive days can significantly reduce the
blood lipid levels [22]. A study also reported that Mk LE
inhibits platelet aggregation, resulting in improved blood
flow [23]. It also acts as an antioxidant, further suppress-
ing the vascular inflammatory response through reduced
reactive oxygen species (ROS) production [26].
Presently, several animal models have been used to
study hyperlipidemia induced atherosclerosis, like
mice [27], zebrafish [28], rats [29, 30], and pigs [31].
To study the effect of curry leaves on thermally oxi-
dized oil-induced hypercholesterolemia and athero-
sclerosis selection of experimental animal models is
very critical to conduct basic research and develop a
study tool. In this respect, to study human hyperlipid-
emia the rabbit has become the most appropriate ani-
mal model because of rabbits’ unique features of lipid
metabolism similar to humans [32, 33]. Several stud-
ies also used rabbit model for cardiac diseases [34].
Rabbit as an experimental animal is also considered
appropriate for the Rabbit as an experimental animal
model is also used to evaluate the medicinal effects of
several herbal medicines, like the hypolipidemic effect
of Ficus bengalensis [35], the hypoglycemic effect of
Achyranthes aspera [36] antihyperglycemic effects of
Alpinia galanga rhizome and its extracts [37], and
hypoglycemic effects of M. koenigii [25].
In Pakistan, commercially available oils are mostly a
blend of two or more edible oils, and the most common
available blend of an equal ratio of olive, canola, and
sunflower oils was focused in this study, to have the
model that mimics the human situation. Vegetable oils
are repeatedly heated when used for food processing
(frying) at household and commercial levels. We used
repeatedly heated mixed vegetable oils (RHMVO) to in-
duce hyperlipidemia and atherosclerosis. We designed
this study to investigate the medicinal effects of curry
leaves in different doses, in RHMVO-induced athero-
sclerotic models.
Methods
Collection and identification of oils and plant material
Fresh curry leaves, standard food-grade canola, sun-
flower, and olive oils were purchased from Karachi local
market. The specimen of plant material and oils were
verified by the Department of Pharmacognosy, Univer-
sity of Karachi.
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Oil sample preparation
Olive, canola, and sunflower oils were mixed in equal ra-
tio and heated beyond the smoke point of the oil mix-
ture at 220 °C for 45 min each day for a total of ten days
[38–40]. The smoke point for olive oil, canola oil, sun-
flower oil is 180 °C, 200 °C, and 225 °C, respectively [41,
42]. Every day before heating, the oil level was adjusted
in the pan with the same oils blend (0.007 ± 0.003 l per
day) to meet the initial level. This replenishment method
was adopted to replicate the same practices used in fried
and fast food outlets [38]. At the end of the 10th day,
viscous dark brown oil was obtained. To prevent photo-
degradation it was stored in amber color bottles and la-
beled as RHMVO [43].
Preparation of Murraya koenigii leaves extract (Mk LE)
Curry leaves were cleaned by thorough washing to re-
move any contamination with double-distilled water.
Washed curry leaves were dried in shade at room
temperature and grounded to powder with the help of a
mechanical grinder and then preserved at room
temperature in an airtight container. Three hundred
grams powdered leaves were subjected to cold extraction
by stirring them in 4-l double-distilled water for 24 h.
The resultant suspension was centrifuged at 10,000×g
for 10 min and filtered through Whatman No. I filter
paper, followed by a 0.45 μm membrane filter (Sartorius
minisart, Hannover, Germany). Finally, the filtrate was
dried using a rotary evaporator and resulted in a 13.6%
yield. The dried extract was dissolved in distilled water
to achieve 100 mg/ml stock. Crude aqueous extract of
curry leaves (Mk LE) was then kept at 4 °C storage
temperature for subsequent use for planned
experiments.
Experimental animals
Healthy adult male rabbits of local strain weighing be-
tween 1450 ± 10 g were purchased from the department
of pharmacology, University of Karachi, Pakistan. Male
rabbits were selected to avoid the sex difference due to
female sex hormonal effects on CVDs [44, 45]. Secondly,
the prevalence of plasma lipid abnormalities in Pakistan,
are higher in males than females [46, 47]. Rabbits were
kept individually in wire-topped steel cages with a
wooden bottom, under controlled humidity (50–60%),
and temperature (23 °C ± °C) with 12/12 h light/dark
photo-cycle. Animals were acclimatized for 7 days before
starting the experiment. Animals were handled accord-
ing to the institutional animal’s ethical committee
guidelines.
Experimental design
The total experimental period was of 26 weeks and all
animals were divided into five groups (n = 10). In the
first 16 weeks, except for the control, all other groups
were treated with 2 ml/kg/day of RHMVO to induce
hypercholesterolemia [43]. The induction period was
followed by the treatment period of 10 weeks. In the
treatment period animals were treated as follows
 Control group: Untreated
 RHMVO group: Rabbits continued to have 2 ml/kg/
day RHMVO
 Mk LE-300 group: Rabbits were given Mk LE 300
mg/kg/day
 Mk LE-500 group: Rabbits were given Mk LE 500
mg/kg/day
 Statin group: Rabbits were given lovastatin 0.5 mg/
kg/day
From the statin group, we selected lovastatin, to avoid
the additional side effects (nasopharyngitis, diarrhea, and
urinary tract infection) which are associated with other
statins [48]. Oil and Mk LE were administered daily in
the morning and lovastatin in the evening through the
oral route, with the help of oral syringes [49]. Lovastatin,
a short-acting statin, is prescribed to be taken in the
evening to achieve better results as cholesterol produc-
tion through livers enzymes is higher in these hours [50,
51]. For the rest of the day animals of all the groups
were fed ad libitum on a regular normal diet (fresh hay
and water). Morbidity and mortality were monitored
through the study period. Animal’s body weight was re-
corded at baseline, week 1, 16, 20, 23, and 26. After the
induction period (at 16 weeks) and treatment period (at
26 weeks), 3 rabbits from each group were euthanized
through the intravenous administration of sodium
pentobarbital 100 mg/kg followed by decapitation [52].
Furthermore, animals were necropsied for histopatho-
logical examination of internal organs and to retrieve
liver, heart, spleen and kidney for organs weight
evaluation.
Blood sample collection for lipid profile and liver function
markers
Blood samples were collected from the ear vein of an-
imals at week 1, 16, 20, 23, and 26. For hematological
parameters, 2 ml blood was collected in EDTA and 5
ml in gel vacutainers to perform the biochemical as-
says. Blood was centrifuged to collect plasma and
serum and stored at − 20 °C until used further to
analyze the plasma lipid profile (TG, TC, HDL, LDL,
VLDL) and liver function markers, such as total pro-
tein, albumin, serum glutamic-pyruvic transaminase
(SGPT), serum glutamic-oxaloacetic transaminase
(SGOT) and alkaline phosphatase (ALP) using com-
mercially available kits (RANDOX Laboratories Ltd)
followed by manufacturer’s instructions.
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Oxidative stress and tissue damage parameters
Lipid peroxidation was measured by determining plasma
malondialdehyde (MDA), following Kikugawa et al
method [53]. The plasma C-reactive protein (CRP) was
measured by using an ELISA kit (Abnova, Taipei,
Taiwan), as per the manufacturer’s instruction. A com-
mercially available kit was used to analyses lactate de-
hydrogenase (LDH) (BioVision, USA). We followed
Hamsi et al. method to prepare the samples and stan-
dards [54]. Sheu et al. method was adopted to measures
the fasting plasma homocysteine concentrations [55].
Creatine phosphokinase (CPK) was measured by a com-
mercially available kit from Beckman Coulter, Brea,
USA, following manufacturer instructions.
Atheroma measurement
After 26 weeks animals were sacrificed as per the guide-
lines and necropsied to dissect a 10 cm aortic arch from
the aortic valve and washed in normal saline followed by
further dissection to open the orifice of the carotid ar-
tery (5 cm long) with a longitudinal cut. After removal of
adhered tissue, propylene glycol (100%) was used to de-
hydrate the aorta, for 10 min followed by another 10 min
staining 0.7% Sudan IV (in propylene glycol) [56–58].
The tissue was re-hydrated by treating it with 85% pro-
pylene glycol for 5 min, washed with distilled water, and
photographed. Digital Image Analyzer was used to
analyze the red atheromatous plaques. We measured the
degree of lipid deposition by calculating the percent ath-
erosclerosis index (AI) through the ratio between the
Sudan-positive area to the whole aortic wall area.
Microscopic examination
After weighing liver tissues, samples were treated with
alcohol to dehydrate. After cleaning with xylene, samples
were further embedded in paraffin at 56 °C. By using a
rotatory microtome, 5 μm sized sections were obtained,
mounted onto albumenized slides, and kept for drying
for 12 h. Dewaxing was done in xylene and hydration
was performed in ethanol and water. The sections were
first treated with Harris hematoxylin to stain, thereafter
differentiation by acid alcohol, and then staining in
methylene blue was performed. Furthermore, dehydra-
tion of sections in alcohol (95%) and staining in alco-
holic eosin (10%), dehydration with absolute alcohol,
and cleaning with xylene were completed. The sections
were then mounted using Canada balsam. These pre-
pared slides were finally viewed with the use of a light
microscope.
Phytoconstituents determination of Mk LE
For the quantitative measurement of the total content of
flavonoids and phenols in the Mk LE, we followed the
methods of Sefi et al [59]. Total phenol content is
mentioned in mg gallic acid equivalents (GAE) per each
gram of extract, where GA was considered as standard.
Total flavonoids are mentioned as mg catechin equiva-
lents (CE) per each gram of extract, catechin was used
as standard. For the quantitative finding of the total al-
kaloid content in the Mk LE, we followed the method of
Sreevidya et al [60] and expressed as mg/g bismuth ni-
trate. Total tannin content was evaluated by following
the Polshettiwar et al method [61] and expressed as tan-
nic acid equivalent per gram of Mk LE. Total chloro-
phyll content was evaluated by following the method
adopted in Kizhedath and Suneetha study [62] and
expressed as mg pigments/gm.
Statistical analysis
Data is represented in the form of mean ± standard devi-
ation. We applied analysis of variance (ANOVA)
followed by post hoc Tukey’s honest significant differ-
ence (HSD) test to find out statistical significance at p <
0.05. Statistical product and service solutions software
was used.
Results
Biometric parameters
No death and unexpected signs and symptoms noticed
in experimental animals throughout the study period in
the treated animals and control. The body and organ
weights of animals in all the groups increased gradually
with age (Table 1 and Fig. 1). Bodyweight of all the ani-
mals treated with RHMVO was significantly higher than
control, after the induction period of 16 weeks. At 26
weeks animals in the RHMVO group exhibited signifi-
cantly higher weight than the age-matched other groups.
However, statistically insignificant differences were
present in the bodyweight of Mk LE-300, Mk LE-500
and lovastatin groups at 20th week, but at the end of
26th week, this phenomenon became very considerable
and statistically significant body weight reduction was
observed in Mk LE treated groups in a dose-dependent
manner compared to RHMVO fed group (p < 0.05).
Moreover, weight reduction was also statistically signifi-
cant in the lovastatin treated group (p < 0.05), but lesser
than the Mk LE-500 group. As shown in Table-1 organs
weight reduction of Mk LE treated groups in the treat-
ment phase was dose-dependent and statistically highly
significant (p < 0.005) in 500 mg/kg/day doses. Organ
weight reduction in Mk LE-500 treated group was even
higher than the lovastatin treated group.
Serum biochemical analysis of lipid profile
As shown in Table 2, animals in RHMVO exhibited
higher TGs, TC, LDL, VLDL, and lower HDL circulating
levels in comparison with control. After 26 weeks of
RHMVO feeding the TGs and TC values increased
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about 4–5 folds in the RHMVO group. Whereas in Mk
LE treated groups all these parameters improved in a
dose-dependent manner and statistically significant
(p > 0.05) changes were observed in Mk LE-500 and lov-
astatin groups. Although, at weeks 20 and 23 there was
no such obvious difference between Mk LE-300, Mk LE-
500, and statin groups. But at the end of 26 weeks Mk
LE-500 group animals presented significantly (p > 0.005)
improved lipid profile than Mk LE-300 and comparable
to statin group. At the end of treatment HDL levels were
significantly higher in the Mk LE-500 group compared
to the control group.
Hepatic function and oxidative stress markers
The biochemical analysis of liver function markers has
shown that continuous feeding of RHMVO induced
hypercholesterolemia, which resulted in significantly
(p < 0.005) reduced total protein and albumin levels. The
blood levels of LDH, CPK, SGOT, SGPT, and ALP were
also increased significantly, suggestive of liver
Fig. 1 Graphical Presentation, Comparing the Weight Gain in Different Groups During the Study Period (at 95% CI): (Control = Blue line showing
the gradual increment in bodyweight with age, RHMVO fed group = Green line showing significant weight gain, Mk LE-300 group = Brown
line showing the weight reduction over week 16 to 26, lovastatin group = Red line showing significant weight reduction, Mk LE-500 group =
Purple line showing the significant weight reduction comparable with red line of lovastatin group
Table 1 Comparison of organs weight post-induction and after-treatment
Organs Observation Time Control (weight-g) RHMVO (weight-g) Mk LE-300 (weight-g) Mk LE-500 (weight-g) Lovastatin (weight-g)
Liver Post induction (week16) 53.66 ± 1.35 86.25 ± 2.62 87.38 ± 1.88 85.26 ± 1.92 86.24 ± 2.22
After treatment (week26) 60.31 ± 4.33 104.95 ± 2.6 ## 83.76 ± 1.89 63.17 ± 2.56 ** 75.51 ± 2.26*
Spleen Post induction (week16) 34.37 ± 1.47 56.89 ± 2.15 57.1 ± 2.25 55.75 ± 3.09 55.09 ± 3.46
After treatment (week26) 40.88 ± 3.42 74.96 ± 4.5 # 54.08 ± 2.26 42.48 ± 1.2** 51.27 ± 2.52
Heart Post induction (week16) 18.08 ± 1.39 34.75 ± 0.9 34.92 ± 1.09 34.9 ± 1.14 34.95 ± 1.15
After treatment (week26) 18.54 ± 5.92 49.17 ± 4.84 # 32.83 ± 1.09 29.31 ± 1.14* 31.86 ± 1.12
Kidney Post induction (week16) 14.41 ± 0.9 27.74 ± 1.53 27.97 ± 1.63 27.77 ± 1.74 28.11 ± 1.94
After treatment (week26) 17.98 ± 2.43 37.16 ± 2.18 ## 25.99 ± 1.28 21.05 ± 1.38* 25.6 ± 0.55
*Significantly reduced from post-induction weight (p < 0.05)
**Significantly reduced from post-induction weight (p < 0.005)
# significantly increased from the post-induction weight (p < 0.05)
## Significantly increased from post-induction weight (p < 0.005)
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dysfunction with reduced protein synthesis and hepatic
injury. With the treatment of Mk LE, hepatic function
markers were restored in a dose-dependent manner, but
significantly in Mk LE-500 group (p < 0.005). In lova-
statin (0.5 mg/kg/day) treated group few parameters im-
proved significantly after 10 weeks of treatment (p <
0.05).
At the end of the induction period, oxidative stress
and inflammation were also significantly (p < 0.005) in-
creased with RHMVO feeding, shown by elevated MDA
and CRP levels. Mk LE in higher doses of 500 mg/kg
was enough to restore the normal levels after 10 weeks
of treatment (p < 0.005). Lovastatin (0.5 mg/kg/day)
treated group exhibited a lesser impact on inflammatory
and oxidative stress markers over 10 weeks period
(Table 3).
Chemical analysis of the extract
Dry powder of curry leaves yielded 13.6% components by
weight (water-soluble). The quantitative characterization
Table 2 Comparison of lipid profile through the study period (baseline till week-26)
Observation Time Control RHMVO Mk LE-300 Mk LE-500 Lovastatin
TRIG (mg/dl)
week 1-baseline (Before induction) 56.32 ± 3.51 55.43 ± 2.21 55.62 ± 3.28 57.08 ± 3.80 56.58 ± 3.18
week 16 (Post induction) 69.08 ± 2.92 272.18 ± 1.76** 279.61 ± 6.76** 281.4 ± 6.03** 276.01 ± 12.31**
week 20 73.17 ± 2.11 309.26 ± 1.83** 251.83 ± 6.16 256.01 ± 6.19 255.67 ± 12.05
week 23 74.75 ± 3.42 330.61 ± 1.55** 220.05 ± 6.28 218.76 ± 5.05 224.46 ± 12.92
week 26 75.93 ± 4.0 352.07 ± 6.74** 179.06 ± 6.09 # 166.51 ± 3.08 ## 195.2 ± 12.41#
TC (mg/dl)
week 1- baseline (Before induction) 141.02 ± 3.21 140.12 ± 3.25 141.21 ± 5.02 141.30 ± 3.55 141.25 ± 1.58
week 16 (Post induction) 148.54 ± 4.25 444.5 ± 8.23** 446.31 ± 8.59** 450.35 ± 8.91** 443.29 ± 11.61**
week 20 150.19 ± 5.23 503.45 ± 8.09** 394.07 ± 8.23 378.1 ± 8.09 388.08 ± 11.06
week 23 151.84 ± 3.02 562.4 ± 8.55** 350.75 ± 7.99 289.85 ± 8.23# 333.82 ± 11.31
week 26 154.4 ± 3.87 637.75 ± 9.99** 308.51 ± 8.32# 200.59 ± 8.59## 280.61 ± 11.38##
LDL (mg/dl)
week 1- baseline (Before induction) 48.23 ± 3.29 47.22 ± 1.29 48.01 ± 3.31 47.59 ± 3.98 47.29 ± 3.19
week 16 (Post induction) 67.66 ± 3.31 367.61 ± 15.22** 366.21 ± 18.30** 363.57 ± 14.69** 361.63 ± 14.17**
week 20 68.87 ± 3.06 405.59 ± 18.23** 351.9 ± 15.09 326.36 ± 14.09 326.62 ± 14.29
week 23 69.72 ± 3.25 439.84 ± 10.59** 333.59 ± 11.66 271.24 ± 11.05 278.36 ± 10.09
week 26 73.92 ± 2.88 481.22 ± 75.05** 311.35 ± 18.36 213.59 ± 10.29## 240.65 ± 12.07#
VLDL (mg/dl)
week 1- baseline (Before induction) 11.08 ± 0.56 11.22 ± 0.77 11.21 ± 0.81 11.10 ± 0.67 11.02 ± 0.66
week 16 (Post induction) 14.88 ± 0.74 82.18 ± 3.97** 82.73 ± 4.49** 84.27 ± 4.29** 82.55 ± 3.89**
week 20 15.84 ± 0.70 90.43 ± 3.29** 77.52 ± 4.20 73.06 ± 5.20 72.38 ± 3.34
week 23 16.65 ± 0.62 98.68 ± 5.02** 70.31 ± 4.35 55.85 ± 4.35# 60.49 ± 3.09
week 26 16.52 ± 0.53 105.55 ± 3.07** 62.2 ± 2.21 30.64 ± 4.04## 48.51 ± 4.52#
HDL (mg/dl)
week 1- baseline (Before induction) 53.23 ± 8.69 53.33 ± 7.05 53.53 ± 6.05 54.59 ± 6.29 53.09 ± 8.34
week 16 (Post induction) 69.64 ± 3.35 16.08 ± 1.67$$ 15.78 ± 2.17$$ 15.03 ± 2.22$$ 15.03 ± 2.19$$
week 20 70.92 ± 6.09 13 ± 1.38$$ 21.99 ± 2.01 32.18 ± 2.56^ 24.28 ± 2.65
week 23 71.18 ± 2.95 9.32 ± 2.08$$ 40.08 ± 3.55^ 67.43 ± 4.05^^ 34.63 ± 5.29^
week 26 73.92 ± 5.01 5.64 ± 2.59$$ 58.06 ± 3.23^ 81.68 ± 2.92^^ % 42.89 ± 4.84^
**highly significant difference (p < 0.005) (increased values) than week 1- baseline (Before induction) values
# significant difference (p < 0.05) (decreased values) than week 16- (post induction) values
## highly significant difference (p < 0.005) (decreased values) than week 16- (Post induction) values
$$ highly significant difference (p < 0.005) (decreased values) than week 1- baseline (Before induction) values
^ significant difference (p < 0.05) (increased values) than week 16- (post induction) values
^^ highly significant difference (p < 0.005) (increased values) than week 16- (post induction) values
% significant difference (p < 0.05) (increased values) than control group in corresponding weeks
TRIG Triglycerides, TC Total cholesterol, LDL Low-density lipoproteins, VLDL Very-low-density lipoproteins, HDL High-density lipoproteins
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of the chemical in Mk LE showed the significant existence
of alkaloid, flavonoid, chlorophyll, polyphenol, and tannin
(Table 4).
Effect on atheromatous plaques area
As shown in Fig. 2, at the end of 26 weeks RHMVO
feeding resulted in extensive atheromatous plaques for-
mation, covered about 80–85% of the aortic arch. This
atheromatous plaque was noticeably attenuated by Mk
LE in a dose-dependent manner at the end of the treat-
ment phase. Atheromatous plaque reduced to 60 and
40% in 300 mg and 500mg Mk LE doses respectively.
The atheroma area was reduced by lovastatin (0.5 mg/
kg/day) to 57% after 10 weeks of treatment.
Hepatic histological observations
Under the microscopic observations, widespread lipid
accumulation was observed in hepatocytes in the
RHMVO group (Fig. 3). The point of interest is the
remarkable dose-dependent attenuation of RHMVO-
induced hepatic steatosis with Mk LE treatment. The ef-
fect of Mk LE-500 is greater than the lovastatin.
Discussion
Alternative medicines are getting an important place to
manage different health problems and rising as a wide
field of research. Management of hyperlipidemia-
induced atherosclerosis also relies on alternative
medicine as an upcoming changed trend to protect and
treat. Using the animal model, we created a real-life sce-
nario and induced hyperlipidemia and atheroma forma-
tion with RHMVO and considered herbal nutritional
sources to manage it.
The results of this study establish that Mk LE has the
potential to treat the RHMVO-induced hyperlipidemia
and atherosclerosis. The extract is found as a rich source
of polyphenols, alkaloids, chlorophyll, and flavonoids.
The quantitative analysis of curry leaves aqueous extract
reported that there are constituents with antioxidant
properties, the main reason for using curry leaves as al-
ternative medicines and nutritional supplements in oxi-
dative stress-induced disease studies [63–65]. Mk LE,
with its immense health benefits, has been reported as a
protective remedy against oxidative stress-induced dia-
betes [66]. The aqueous extract of curry leaves also has
prolific antioxidant activities against lead and cadmium-
induced oxidative stress in animal models [66, 67]. Sev-
eral in vivo [68, 69] and in vitro [70, 71] studies reported
the free-radical scavenging ability and antioxidant poten-
tial of curry leaves extract concluding the immediate and
strong ameliorative actions for treating oxidative stress.
Considering the same facts, in this study we evaluated
the dose-dependent effect of curry leaves, to treat the
hyperlipidemia and oxidative stress induced by the high
dose of thermally oxidized cooking oils blend. The im-
pact was also compared with standard i.e. lovastatin
Table 3 Comparison of oxidative stress and liver function markers at week-26
Variables Control ## RHMVO** Mk LE-300 Mk LE-500 Lovastatin
CPK (U/L) 148.17 ± 2.29 1116.85 ± 9.27 981.81 ± 8.55** 562.84 ± 13.78 ** ## 947.84 ± 17.41** #
LDH (U/L) 212.44 ± 45.38 1214.21 ± 9.71 986.64 ± 4.86** # 508.13 ± 9.05 * ## 831.42 ± 12.85 ** #
Homocysteine (μMol/L) 4.62 ± 0.54 15.88 ± 1.08 10.57 ± 1.33* # 5.26 ± 1.04 ## 11.33 ± 0.91**
MDA (nMol/ml) 8 .00 ± 1.43 29.7 ± 1.32 20.68 ± 2.42** # 12.14 ± 1.69 * ## 19.77 ± 1.71 ** #
CRP (mg/dl) 0.04 ± 0.01 14.64 ± 2.16 11.93 ± 1.52** # 4.39 ± 1.57 * ## 9.81 ± 0.98**
SGPT (U/L) 92.9 ± 4.65 376.23 ± 8.33 305.5 ± 2.85** 208.93 ± 70.98 * ## 301.82 ± 10.57**
SGOT (U/L) 95.28 ± 5.11 404.28 ± 8.77 311.41 ± 3.91** 185.3 ± 35.78 * ## 315.42 ± 6.45**
ALP (U/L) 82.89 ± 4.8 635.25 ± 4.98 556.35 ± 3.07** 217.2 ± 9.26 * ## 355.59 ± 6.82** #
Total Protein (mg/dl) 7.42 ± 0.43 2.5 ± 0.24 3.51 ± 0.25* 5.45 ± 0.29 * # 2.11 ± 0.13**
Albumin (mg/dl) 3.42 ± 0.46 1.08 ± 0.04 2.06 ± 0.05# 3.09 ± 0.12## 1.56 ± 0.43*
*Significantly different from Control (p < 0.05). #significantly different from RHMVO (p < 0.05). **Significantly different from Control (p < 0.005). ##significantly
different from RHMVO (p < 0.005)
Table 4 Quantitative extraction yield and chemical content of Mk LE
Sample Extraction yields Chemical composition
(%) = weight of sample
extract /sample
weight) × 100
Total phenols (mg
gallic acid equivalent
/g Mk LE)
Total flavonoid (mg
catechin equivalent.
/g Mk LE)
Chlorophyll
content (mg/
g Mk LE
Alkaloid content
(mg bismuth
nitrate/g Mk LE)
Total tannin (mg
tannic acid
equivalent /g Mk LE)
M.koenigii leaf
aqueous extract
(Mk LE)
15.63 ± 0.46 46.78 ± 0.07 6.1 ± 0.36 0.40 ± 0.009 37.9 ± 0.28 0.129 ± 0.008
Values represented as means ± SD
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from the statin group. Mk LE at a dose of 500 mg/kg
was found effective in a shorter period, to treat oxidative
damage and hyperlipidemia mediated by RHMVO com-
pared to 300 mg/kg. The histopathological and macro-
scopic results showed that to treat RHMVO-induced
atherosclerosis the effect of MK LE in 500 mg/kg of
body weight is comparable with lovastatin, as all the
study parameters were significantly reduced in the Mk
LE-500 group.
Thermally oxidized oil is the most significant source
of oxidative damage for human health if used daily for a
long time. In RHMVO fed groups, highly elevated levels
Fig. 2 Atheroma formation and resolution at the end of 26 weeks: (a) Control; with no atheromatous plaques formation (b) RHMVO fed group;
extensive atheromatous plaques formation, covered about 80–85% of the aortic arch (c) Mk LE-300 group; atheromatous plaque reduced to 60%
(d) Mk LE-500 group; atheromatous plaque reduced to 40% (e) lovastatin group; Atheromatous plaque reduced to 57%
Fig. 3 Histopathological finding of rabbits’ liver after 10 weeks of treatment. Control: a microscopic view of a normal liver. RHMVO fed group: a
microscopic view of fatty liver showing distended hepatocytes due to fat vacuoles. Mk LE-300 group: observed a lesser number of fat vacuoles
in the portal area. Mk LE-500 group: observed an insignificant number of fat vacuoles. Lovastatin group: observed an insignificant number of fat
vacuoles (200x magnification)
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of SGOT (extremely sensitive and a precise biomarker
for hepatotoxicity) and ALP (a main biomarker of hep-
atic and biliary defects like cholestasis) [72] reflected he-
patocytes damage and tissue interruption, allowing the
leakage of intracellular enzymes in blood [73]. The liver
is damaged by excessive free radicals and may result in
hepatitis, cirrhosis, and hepatic tumor [74]. Consistent
with the diminished serum albumin and total protein
levels and supported by the significantly enlarged liver
and histopathological changes in hepatocytes of
RHMVO fed rabbits. The results of our study are con-
sistent with the previous study, reported significantly re-
duced serum SGPT and SGOT levels in curry leaves
pretreated groups against the lead-induced model, a
clear indication of hepatic protection [75, 76], but the
maximum effective dose of curry leaves was 100 mg/kg
body weight.
The noticeable presence of carbazole alkaloids and
tannins in Mk LE analysis exhibit excellent hepatopro-
tective activity through their anti-lipid peroxidation and
antioxidant potential [77]. In the present study, Mk LE
considerably inhibited fat accumulation in hepatocytes
and the formation of hypercholesterolemia-induced ath-
eroma. Besides, curry leaves extract attenuated lipid per-
oxidation and oxidative membrane injury in the organs
showing lipidosis. Statins are preferentially prescribed to
improve blood lipid profile through suppressing hepatic
cholesterol synthesis [11]. However, it’s reported in pre-
vious studies that long-term use and over-dosage of the
statins results in severe hepatotoxicity, whereas low
doses failed to control blood cholesterol levels effectively
from the diet [10–12]. Statins are reported to produce
adverse effects in up to 33% of patients [78]. Notably,
the management of cerebrovascular and cardiovascular
disease risk factors in preventive mode is more effective
than the therapeutic mode, as after the outbreak of these
diseases time to death is very short [11]. Therefore, it
has been recommended to follow dietary restrictions
and choose appropriate oils and fats. In addition, the ex-
cessive consumption of oils and fats especially in ther-
mally oxidized form is also known to cause vascular
diseases, such as reduced vasorelaxation responses,
endothelial malfunction [16], lipid peroxidation [17],
atherosclerosis, and oxidative stress [19].
Reactive oxygen species (ROS) are free radicals with one
or more unpaired electrons. Major ROS include super-
oxide anion, hydrogen peroxide, and the hydroxyl radical
[79]. In addition to ROS, reactive nitrogen species (RNS),
including peroxynitrite (NO3-), nitric oxide radical (NO),
and S-nitrosothiols, also contribute to the generation of
oxidative stress. ROS are often generated as byproducts of
cellular metabolic reactions and exogenous induction.
These ROS produce homeostatic imbalances, and over-
whelm cellular antioxidants defense system and results in
oxidative stress, that further damage biomolecules such as
proteins, nucleic acids, and lipids which eventually, in-
duces cell death and tissue injury [80, 81]. Subsequently
promotes the development of age-dependent diseases, like
cancer, atherosclerosis, arthritis, etc. [82]. MK LE has sev-
eral potent antioxidants, such as isomahanine, isolongifo-
lene, mahanine, mahanimbine, koenimbine,girinimbine,
koenoline, and O-methylmurrayamine [83, 84]. These an-
tioxidants exhibit 2,2-diphenyl-1-picrylhydrazyl (DPPH)
free radical scavenging activity, inhibition of NO radical,
and thiobarbituric acid reactive substances (TBARS) activ-
ity [85, 86].
Mitochondria are the powerhouse of the living cell
and play a vital role in scavenging free radicals and con-
trolling programmed cell death and/or the apoptosis-
signaling pathway [87]. RHMVO-induced mitochondrial
damage results in decreased adenosine triphosphate
(ATP) production, increased ROS generation, impaired
calcium buffering, damage to mitochondrial DNA
(mtDNA). An altered mitochondrial morphology and al-
terations in mitochondrial fission and fusion. Mitochon-
drial dysfunction is characterized by a loss of efficiency
in the electron transport chain, as well as reductions in
the synthesis of high-energy molecules [88]. Mitochon-
drial dysfunction is a characteristic of all chronic dis-
eases including neurodegenerative disorders, CVDs,
diabetes, auto-immune diseases, atherosclerosis, and
others [89, 90].
Recent studies have evaluated the neuroprotective
activities of compounds isolated from MK LE. A
study reported that the bioactive compounds present
in MK LE exhibited the ability to repair the mito-
chondrial damage and restore the mitochondrial
membrane potential levels [91–93]. Previous findings
have demonstrated that MK LE and its primary active
compounds regulate multiple signaling pathways, in-
cluding phosphatidylinositol 3 kinase (PI3K)/protein
kinase B (AKT), mammalian target of rapamycin
(mTOR) and mitogen-activated protein kinase
(MAPK). M. koenigii and its primary active com-
pounds exert complementary effects on oxidative
stress and the alteration of proteins [94, 95].
The lipid-lowering activity of MK LE is reported in
several animal studies, in the different doses, in the
range of 80–600mg [20, 21, 23]. To our knowledge, this
is the first animal study that evaluated the effect of MK
LE, in RHMVO-induced hypercholesterolemia in ani-
mals, also using the standard (lovastatin). In the dose of
500 mg/kg MK LE significantly reduced the TG, total
cholesterol, LDL, and VLDL, also, increased HDL levels
and reduced the cardiac infarction risk through the re-
covery of the arterial endothelial cells functions [96].
Better response with high doses is also supported by
other studies [20, 97]. The requirement of a longer
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duration to treat dyslipidemia is also supported by a pre-
vious study [97].
The high value of CRP is possibly indicative of devel-
oping cardiovascular disease, active inflammation, bac-
terial infection [98], and inflammatory bowel disease,
and other similar conditions like intestinal lymphoma
and tuberculosis [99]. Overexpression of CPK, homo-
cysteine, and LDH has been linked with the number of
disorders including tissue damages, ROS induced inflam-
mation, and endothelial cell injury [100]. The elevated
levels of all these tissues damaging markers are suggest-
ive of increased risk of hypertension, diabetes, and CVDs
[101, 102]. Reduction in these parameters along with re-
duced oxidative stress is an additional benefit of MK LE,
compared to statins.
Moreover, it was demonstrated that MK LE inhibits
platelet aggregation when given with coriander extract
[23], thus further explains the MK LE potential to treat
RHMVO-induced atherosclerosis. Formation of
thrombus and atherosclerosis takes place when vascular
endothelial walls get injured during oxidized LDL-
mediated oxidative reactions and activated platelets get
attached to this area. Therefore, curry leaves extract can
be the alternate option for investigators to treat hyper-
lipidemia, oxidative stress, and atherosclerosis medicated
by consumption of a higher amount of RHMVO in daily
life.
Conclusion
The results of this study conclude that Mk LE exhibits
potent antioxidant and antidyslipidemic properties that
can be used to treat RHMVO-induced hyperlipidemia
and atherosclerosis in optimal doses and duration. Over
the past few decades, the prevalence of coronary artery
diseases has increased significantly in South Asians and
predicted to be more than 24 million in 2035. Curry
leaves are basically of south Asian origin, so it can be
the better, easier, and cheaper option as nutrient supple-
ment and remedy.
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